Dr. Arun Menawat Purchases 20,000 Shares of Profound Medical (TSE:PRN) Stock

Profound Medical Corp. (TSE:PRN) Director Dr. Arun Menawat purchased 20,000 shares of Profound Medical stock in a transaction on Friday, March 20th. The shares were purchased at an average cost of C$6.96 per share, with a total value of C$139,200.00. Following the transaction, the director owned 658,660 shares in the company, valued at approximately C$4,584,273.60. The trade was a 3.13% increase in their ownership of the stock.

Profound Medical Stock Performance

Shares of PRN opened at C$8.88 on Monday. The stock has a market capitalization of C$322.29 million, a price-to-earnings ratio of -6.30 and a beta of 1.07. Profound Medical Corp. has a 12 month low of C$5.23 and a 12 month high of C$12.40. The firm has a fifty day simple moving average of C$8.89 and a 200 day simple moving average of C$9.03. The company has a current ratio of 12.52, a quick ratio of 14.98 and a debt-to-equity ratio of 7.09.

Profound Medical (TSE:PRN) last issued its quarterly earnings results on Thursday, March 5th. The company reported C$0.37 EPS for the quarter. The firm had revenue of C$8.00 million for the quarter. Profound Medical had a negative net margin of 248.45% and a negative return on equity of 85.73%. Research analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.